Oova, the fertility translator that fully illuminates a woman's fertility, has announced it has secured $10.3 million in new investment capital from investors. This funding round marks a significant milestone for the company, which provides women and their care teams with clear, data-driven steps to conception.
Founded by doctors and backed by Mount Sinai Hospital, Oova has developed a consumer-first, data-driven experience that benefits both patients and healthcare providers. Its core offering is an at-home urine test designed to measure both luteinizing hormone and progesterone. This dual measurement immediately informs a woman of her most fertile days and accurately confirms ovulation, delivering advanced personalized analytics and real-time action plans with every hormone reading. Oova's approach is transforming the fertility care experience by making sophisticated insights accessible at home.
The $10.3 million in capital will be deployed to accelerate Oova's product development initiatives and expand its market reach. The company plans to invest in further enhancing its technology platform and scaling its operational capabilities to meet increasing demand for its personalized fertility solutions. This investment underscores confidence in Oova's innovative approach to fertility monitoring and management.
Looking ahead, Oova aims to solidify its position as a leader in fertility technology. The company is focused on continuing to empower women with precise, actionable data, ultimately striving to make the path to conception clearer and more efficient for individuals and couples globally.
.png&w=3840&q=75)
